EUVIMEDEUVIMED entdecken
Open Access

Antiplatelet Therapy, Abdominal Aortic Aneurysm Progression, and Clinical Outcomes

Essa Hariri, Milad Matta, Habib Layoun, Osamah Badwan, Lorenzo Braghieri, A Phillip Owens, Robert Burton, Rohan Bhandari, Doran Mix, John Bartholomew, David Schumick, Ayman Elbadawi und 4 weitere

JAMA Network Open · 12.12.2023 · 6 (12) · e2347296

DOI: 10.1001/jamanetworkopen.2023.47296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 12.12.2023. Verfasst von Essa Hariri und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio. Hauptthemen laut MEDLINE: Endovascular Procedures, Aortic Aneurysm, Abdominal. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Preclinical studies suggest a potential role for aspirin in slowing abdominal aortic aneurysm (AAA) progression and preventing rupture. Evidence on the clinical benefit of aspirin in AAA from human studies is lacking.

Objective

To investigate the association of aspirin use with aneurysm progression and long-term clinical outcomes in patients with AAA. Design, Setting, and Participants This was a retrospective, single-center cohort study. Adult patients with at least 2 available vascular ultrasounds at the Cleveland Clinic were included, and patients with history of aneurysm repair, dissection, or rupture were excluded. All patients were followed up for 10 years. Data were analyzed from May 2022 to July 2023. Main Outcomes and Measures Clinical outcomes were time-to-first occurrence of all-cause mortality, major bleeding, or composite of dissection, rupture, and repair. Multivariable-adjusted Cox proportional-hazard regression was used to estimate hazard ratios (HR) for all-cause mortality, and subhazard ratios competing-risk regression using Fine and Gray proportional subhazards regression was used for major bleeding and composite outcome. Aneurysm progression was assessed by comparing the mean annualized change of aneurysm diameter using multivariable-adjusted linear regression and comparing the odds of having rapid progression (annual diameter change >0.5 cm per year) using logistic regression.

Results

A total of 3435 patients (mean [SD] age 73.7 [9.0] years; 2672 male patients [77.5%]; 120 Asian, Hispanic, American Indian, or Pacific Islander patients [3.4%]; 255 Black patients [7.4%]; 3060 White patients [89.0%]; and median [IQR] follow-up, 4.9 [2.5-7.5] years) were included in the final analyses, of which 2150 (63%) were verified to be taking aspirin by prescription. Patients taking aspirin had a slower mean (SD) annualized change in aneurysm diameter (2.8 [3.0] vs 3.8 [4.2] mm per year; P = .001) and lower odds of having rapid aneurysm progression compared with patients not taking aspirin (adjusted odds ratio, 0.64; 95% CI, 0.49-0.89; P = .002). Aspirin use was not associated with risk of all-cause mortality (adjusted HR [aHR], 0.92; 95% CI, 0.79-1.07; P = .32), nor was aspirin use associated with major bleeding (aHR, 0.88; 95% CI, 0.76-1.03; P = .12), or composite outcome (aHR, 1.16; 95% CI, 0.93-1.45; P = .09) at 10 years.

Conclusions

In this retrospective study of a clinical cohort of 3435 patients with objectively measured changes in aortic aneurysm growth, aspirin use was significantly associated with slower progression of AAA with a favorable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endovascular ProceduresAortic Aneurysm, AbdominalAdultHumansMaleAgedRetrospective StudiesPlatelet Aggregation InhibitorsCohort StudiesAspirinHemorrhage

Substanzen

Platelet Aggregation InhibitorsAspirin

Autor:innen und Institutionen

  • Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Division of Cardiology, Johns Hopkins Medicine, Baltimore, Maryland.
  • Cardiovascular Medicine, Section of Vascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati, Ohio.

Förderung

  • NCATS NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Hariri, E., Matta, M., Layoun, H., Badwan, O., Braghieri, L., Owens, A. P., Burton, R., Bhandari, R., Mix, D., Bartholomew, J., Schumick, D., Elbadawi, A., Kapadia, S., Hazen, S. L., Svensson, L. G., & Cameron, S. J. (2023). Antiplatelet Therapy, Abdominal Aortic Aneurysm Progression, and Clinical Outcomes. JAMA Network Open, 6(12), e2347296. https://doi.org/10.1001/jamanetworkopen.2023.47296

Vancouver

Hariri E, Matta M, Layoun H, Badwan O, Braghieri L, Owens AP, et al. Antiplatelet Therapy, Abdominal Aortic Aneurysm Progression, and Clinical Outcomes. JAMA Network Open. 2023;6(12):e2347296. doi:10.1001/jamanetworkopen.2023.47296

BibTeX
@article{Hariri2023,
  author = {Hariri, Essa and Matta, Milad and Layoun, Habib and Badwan, Osamah and Braghieri, Lorenzo and Owens, A Phillip and Burton, Robert and Bhandari, Rohan and Mix, Doran and Bartholomew, John and Schumick, David and Elbadawi, Ayman and Kapadia, Samir and Hazen, Stanley L and Svensson, Lars G and Cameron, Scott J},
  title = {Antiplatelet Therapy, Abdominal Aortic Aneurysm Progression, and Clinical Outcomes},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {12},
  pages = {e2347296},
  doi = {10.1001/jamanetworkopen.2023.47296}
}
Kostenlos starten →